Twin Capital Management Inc. Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Twin Capital Management Inc. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 53,392 shares of the company's stock after selling 1,870 shares during the period. Johnson & Johnson comprises about 1.0% of Twin Capital Management Inc.'s investment portfolio, making the stock its 15th biggest holding. Twin Capital Management Inc.'s holdings in Johnson & Johnson were worth $8,855,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lantz Financial LLC lifted its position in shares of Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. State of Wyoming lifted its position in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the period. Finally, Range Financial Group LLC grew its position in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after acquiring an additional 2,529 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $172.87.

Johnson & Johnson Price Performance

JNJ stock traded up $2.79 during trading on Tuesday, hitting $167.15. The stock had a trading volume of 5,003,485 shares, compared to its average volume of 8,130,207. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market capitalization of $402.17 billion, a P/E ratio of 17.87, a PEG ratio of 2.08 and a beta of 0.41. The company's 50-day moving average price is $154.29 and its two-hundred day moving average price is $155.12.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the company earned $2.82 EPS. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.11%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.